Evogene Deploys ChemPass AI in DMTA Collaboration with Tel Aviv University BCDD
EVGN•Evogene is collaborating with Tel Aviv University’s Blavatnik Center for Drug Discovery to deploy its ChemPass AI engine alongside BCDD’s experimental infrastructure in a coordinated Design-Make-Test-Analyze workflow. The initiative will offer Israeli academic entrepreneurs integrated computational chemistry and translational validation for early-stage small-molecule drug development.
1. Strategic Collaboration Established
Evogene has entered a collaboration with Tel Aviv University’s Blavatnik Center for Drug Discovery, facilitated by the university’s tech transfer arm Ramot, aiming to accelerate small-molecule drug discovery by integrating computational chemistry and experimental infrastructure.
2. Integrated DMTA Workflow
The initiative will leverage Evogene’s proprietary ChemPass AI generative engine alongside BCDD’s state-of-the-art screening and translational validation capabilities in a coordinated Design-Make-Test-Analyze framework to optimize and advance early-stage drug candidates.
3. Benefits for Academic Entrepreneurs
Selected Israeli academic research teams and scientific entrepreneurs will receive access to both computational design tools and experimental validation support, designed to reduce early-stage risk, improve development efficiency, and expand Evogene’s pipeline of novel small molecules.
